Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

NCT02096042 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Slow accrual.

Conditions

Leukemia

Interventions

DRUG: Brentuximab Vedotin
DRUG: 5-Azacytidine

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]